Introduction: Understanding a Critical Cardiovascular Biomarker

When it comes to cardiovascular risk, most people focus on cholesterol, blood pressure, or blood sugar. Yet long before plaques rupture or arteries stiffen, damage begins at a far more subtle level: the endothelium, the delicate inner lining of blood vessels. One of the most powerful and underappreciated biomarkers of endothelial health is asymmetric dimethylarginine (ADMA).

ADMA is not just another lab value. It is a direct inhibitor of nitric oxide production, a driver of vascular dysfunction, and a strong independent predictor of cardiovascular disease, stroke, kidney disease, insulin resistance, and overall mortality. Elevated ADMA often explains why patients develop vascular disease despite “normal” traditional risk markers.

In this comprehensive review, we will explore what ADMA is, why it matters, what causes it to rise, and—most importantly—how to lower it and restore endothelial function using evidence-based nutritional, lifestyle, and integrative strategies.

What Is Asymmetric Dimethylarginine (ADMA)?

Asymmetric dimethylarginine (ADMA) is an endogenous amino acid derivative formed during normal protein turnover. Specifically, it is produced when arginine residues in proteins are methylated by enzymes called protein arginine methyltransferases (PRMTs) and then released into circulation during protein breakdown.

Once released, ADMA enters the bloodstream and competes with L-arginine, the substrate for endothelial nitric oxide synthase (eNOS). By doing so, ADMA inhibits nitric oxide (NO) production. ADMA functions as the principal endogenous inhibitor of nitric oxide synthase (NOS), the enzyme responsible for producing nitric oxide from L-arginine.⁹ By competitively inhibiting NOS activity, ADMA reduces NO bioavailability, thereby impairing endothelium-dependent vasodilation and contributing to endothelial dysfunction.¹⁰ The primary route of ADMA elimination is through enzymatic degradation by dimethylarginine dimethylaminohydrolase (DDAH), with renal excretion playing a secondary role.¹¹

This is critically important because nitric oxide is one of the most protective molecules in human physiology.

Why Nitric Oxide Matters

Nitric oxide is essential for:

• Vasodilation and healthy blood pressure
• Prevention of platelet aggregation and clot formation
• Reduction of vascular inflammation
• Inhibition of smooth muscle proliferation
• Maintenance of arterial elasticity
• Proper insulin signaling

When nitric oxide availability declines, endothelial dysfunction develops. Endothelial dysfunction is the earliest measurable stage of atherosclerosis, occurring years before plaque is visible on imaging.

Because ADMA directly suppresses nitric oxide production, it is now recognized as a causal mediator, not just a marker, of vascular disease.

Why ADMA Is So Clinically Important

Elevated ADMA levels have been associated with:

• Coronary artery disease
• Hypertension
• Stroke
• Chronic kidney disease
• Peripheral arterial disease
• Erectile dysfunction
• Insulin resistance and metabolic syndrome
• Cognitive decline
• Increased all-cause mortality

Importantly, ADMA predicts risk independent of LDL cholesterol, CRP, blood pressure, and glucose. This explains why some patients suffer cardiovascular events despite “good numbers” on standard labs.

In short, ADMA tells you how well your blood vessels are functioning, not just how clogged they are.

ADMA and Cardiovascular Disease

Associations with Coronary Heart Disease and Mortality

Elevated plasma ADMA concentrations have been consistently associated with increased cardiovascular disease (CVD) risk across multiple populations. A comprehensive meta-analysis of prospective studies demonstrated that elevated ADMA levels confer approximately 40% increased risk of cardiovascular events and mortality.¹² This association appears to be independent of traditional cardiovascular risk factors including hypertension, diabetes, and hyperlipidemia. In patients with established coronary heart disease (CHD), ADMA levels are significantly elevated compared to healthy controls, and higher ADMA concentrations predict adverse outcomes including myocardial infarction, heart failure, and cardiovascular death.^13,14

The predictive value of ADMA extends across the spectrum of cardiovascular disease. In patients with acute coronary syndromes, elevated ADMA at presentation is associated with larger infarct size, reduced left ventricular function, and increased short-term and long-term mortality.¹⁵ Among individuals with stable CHD, ADMA levels correlate with the extent and severity of coronary atherosclerosis as assessed by angiography.¹⁶ Furthermore, ADMA has demonstrated prognostic value in heart failure populations, where elevated levels predict disease progression and mortality independent of established biomarkers such as B-type natriuretic peptide.¹⁷

Mechanisms Linking ADMA to Cardiovascular Pathology

The mechanisms by which ADMA contributes to cardiovascular disease are multifaceted. By inhibiting NOS activity, ADMA reduces NO production, leading to impaired endothelium-dependent vasodilation, increased vascular tone, and elevated blood pressure.¹⁸ Reduced NO bioavailability also promotes platelet activation and aggregation, increases leukocyte adhesion to endothelium, and stimulates vascular smooth muscle cell proliferation—all key processes in atherogenesis.¹⁹ Additionally, ADMA-mediated NOS inhibition may lead to NOS uncoupling, a state in which NOS produces superoxide rather than NO, thereby increasing oxidative stress and further impairing endothelial function.²⁰ This creates a vicious cycle of endothelial dysfunction, oxidative stress, and progressive vascular damage.

ADMA and Cerebrovascular Disease

ADMA Elevation in Stroke

The relationship between ADMA and cerebrovascular disease has been investigated in multiple studies, with consistent findings of elevated ADMA levels in stroke patients. Yoo and colleagues reported significantly higher plasma ADMA concentrations in acute ischemic stroke patients compared to healthy controls (2.28±1.63 μmol/L versus 1.46±0.77 μmol/L, respectively).²¹ This elevation appears to occur early in the course of stroke and persists during the acute phase. The magnitude of ADMA elevation correlates with stroke severity, with higher levels observed in patients with larger infarct volumes and more severe neurological deficits.²²

ADMA as a Predictor of Stroke Outcomes

Beyond its association with stroke occurrence, ADMA has prognostic implications for stroke outcomes. Elevated ADMA levels during the acute phase predict poor functional recovery, increased disability at discharge, and higher rates of recurrent vascular events.²³ The mechanisms linking ADMA to adverse stroke outcomes likely involve impaired cerebral perfusion due to reduced NO-mediated vasodilation, increased thrombotic tendency, and exacerbation of ischemic injury through oxidative stress. Some studies have also suggested that ADMA may serve as a marker of pre-existing endothelial dysfunction, identifying individuals at higher risk for both initial and recurrent cerebrovascular events.²⁴

ADMA in Chronic Kidney Disease and Erectile Dysfunction

ADMA and Renal Disease

Chronic kidney disease (CKD) is characterized by markedly elevated ADMA levels, resulting from both decreased renal clearance and reduced DDAH activity.²⁵ ADMA concentrations increase progressively with declining glomerular filtration rate, and patients with end-stage renal disease on dialysis exhibit ADMA levels two to three times higher than healthy individuals.²⁶ This elevation contributes to the exceptionally high cardiovascular mortality observed in CKD populations. ADMA has been identified as an independent predictor of cardiovascular events and all-cause mortality in CKD patients, with predictive value that exceeds traditional risk factors.²⁷ The relationship between ADMA and CKD creates a bidirectional pathophysiological interaction: kidney disease elevates ADMA, which in turn accelerates cardiovascular disease and may contribute to progressive renal dysfunction through effects on renal hemodynamics and endothelial function.

ADMA and Erectile Dysfunction

Erectile dysfunction (ED) is fundamentally a disorder of endothelial function, as penile erection depends critically on NO-mediated smooth muscle relaxation in the corpus cavernosum. Multiple studies have demonstrated elevated ADMA levels in men with ED, with ADMA concentrations correlating inversely with erectile function scores.²⁸ The association between ADMA and ED appears to be independent of age and other cardiovascular risk factors, suggesting a direct pathophysiological role. Importantly, ED and elevated ADMA may both serve as early markers of systemic endothelial dysfunction, often preceding clinically apparent cardiovascular disease by several years.²⁹ This has led to the concept of ED as a “sentinel event” for cardiovascular disease, with ADMA potentially serving as a biochemical link between these conditions.

Factors Influencing ADMA Levels

Testosterone and ADMA

Testosterone exerts significant effects on the L-arginine-NO pathway, with important implications for ADMA metabolism. Testosterone supplementation in hypogonadal men has been shown to reduce plasma ADMA concentrations while simultaneously increasing NO production.³⁰ This effect appears to be mediated through multiple mechanisms, including upregulation of DDAH activity, increased expression of endothelial NOS, and direct effects on endothelial function. The testosterone-ADMA relationship may partially explain the increased cardiovascular risk observed in men with hypogonadism and the potential cardiovascular benefits of testosterone replacement therapy in appropriately selected patients.³¹ Conversely, conditions associated with low testosterone, including aging, obesity, and metabolic syndrome, are characterized by elevated ADMA levels and impaired endothelial function.

Homocysteine and ADMA Interactions

Homocysteine and ADMA represent two distinct but interrelated pathways of endothelial dysfunction. Elevated homocysteine levels have been associated with increased ADMA concentrations, suggesting a mechanistic link between these two cardiovascular risk factors.³² Homocysteine may increase ADMA through inhibition of DDAH activity, as DDAH is sensitive to oxidative stress and homocysteine promotes oxidative damage.³³ Additionally, both homocysteine and ADMA independently impair NO bioavailability through different mechanisms—homocysteine through direct oxidative inactivation of NO and promotion of NOS uncoupling, and ADMA through competitive NOS inhibition. The combination of elevated homocysteine and ADMA appears to confer particularly high cardiovascular risk, with synergistic effects on endothelial dysfunction.³⁴

Oxidative Stress and ADMA Metabolism

Oxidative stress plays a central role in regulating ADMA levels through effects on DDAH activity. DDAH contains a critical cysteine residue in its active site that is highly susceptible to oxidative modification.³⁵ Conditions characterized by increased oxidative stress—including diabetes, hypertension, hyperlipidemia, and smoking—are associated with reduced DDAH activity and consequent ADMA accumulation. This creates a pathological cycle: oxidative stress increases ADMA, which reduces NO production and promotes further oxidative stress through NOS uncoupling. Antioxidant interventions have shown promise in reducing ADMA levels and improving endothelial function in some studies, though clinical translation remains limited.³⁶

Reference Ranges and Measurement Methods

Normal ADMA Concentrations

Establishing reliable reference ranges for ADMA is essential for clinical interpretation. Studies using high-performance liquid chromatography (HPLC), considered the gold standard method, have reported normal plasma ADMA concentrations ranging from 0.34 to 1.10 μmol/L, with a mean value of approximately 0.71 μmol/L in healthy adults.³⁷ Enzyme-linked immunosorbent assay (ELISA) methods typically yield slightly lower values, with reference ranges of 0.25 to 0.92 μmol/L and a mean of 0.57 μmol/L.³⁸ These differences reflect methodological variations rather than true biological differences, emphasizing the importance of method-specific reference ranges. ADMA levels show relatively modest intra-individual variation, with coefficients of variation typically below 15%, supporting its utility as a stable biomarker.³⁹

Analytical Methods and Standardization

Multiple analytical methods have been developed for ADMA measurement, each with distinct advantages and limitations. HPLC with fluorescence detection offers excellent sensitivity and specificity but requires specialized equipment and technical expertise.⁴⁰ Liquid chromatography-tandem mass spectrometry (LC-MS/MS) provides superior analytical performance with the ability to simultaneously measure ADMA, symmetric dimethylarginine (SDMA), and L-arginine, but is expensive and not widely available.⁴¹ ELISA methods offer simplicity and high throughput suitable for clinical laboratories, though concerns about specificity and standardization persist.⁴² The lack of international standardization across methods has hindered widespread clinical adoption of ADMA testing. Efforts to develop certified reference materials and standardized protocols are ongoing and essential for translating ADMA measurement into routine clinical practice.

SDMA as a Complementary Marker

Symmetric dimethylarginine (SDMA), a structural isomer of ADMA, is often measured alongside ADMA. Unlike ADMA, SDMA does not inhibit NOS but is eliminated almost exclusively by renal excretion, making it a sensitive marker of kidney function.⁴³ The ADMA/SDMA ratio may provide additional information beyond either marker alone, with elevated ratios suggesting increased PRMT activity or decreased DDAH activity independent of renal function.⁴⁴ In cardiovascular disease, ADMA typically shows stronger associations than SDMA, consistent with its direct effects on NO synthesis. However, in kidney disease, SDMA may be a more sensitive marker of declining renal function and associated cardiovascular risk.⁴⁵

L-Arginine Pathway and Therapeutic Implications

L-Arginine Supplementation

Given that ADMA competitively inhibits NOS by interfering with L-arginine binding, L-arginine supplementation has been investigated as a potential therapeutic strategy. The rationale is that increasing L-arginine availability might overcome ADMA-mediated NOS inhibition and restore NO production.⁴⁶ Clinical studies have yielded mixed results. Some trials have demonstrated that L-arginine supplementation improves endothelial function, reduces blood pressure, and enhances exercise capacity in patients with cardiovascular disease.⁴⁷ However, other studies, including a large trial in post-myocardial infarction patients, found no benefit or even potential harm from L-arginine supplementation.⁴⁸ These inconsistent findings may reflect the complexity of the L-arginine-NO pathway, including the “arginine paradox”—the observation that NOS activity can be substrate-limited despite apparently adequate intracellular L-arginine concentrations.

Targeting ADMA Metabolism

Alternative therapeutic approaches focus on reducing ADMA production or enhancing its degradation. Strategies to increase DDAH activity or expression could lower ADMA levels and improve NO bioavailability. Several cardiovascular medications, including statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers, have been shown to reduce ADMA levels, potentially contributing to their cardiovascular benefits.⁴⁹ Statins appear to reduce ADMA through multiple mechanisms, including decreased oxidative stress, improved DDAH activity, and reduced PRMT expression.⁵⁰ These findings suggest that ADMA reduction may represent a common pathway through which diverse cardiovascular therapies exert beneficial effects on endothelial function.

Novel Therapeutic Targets

Emerging therapeutic strategies include direct DDAH activators, PRMT inhibitors, and agents that enhance alternative pathways of ADMA elimination. Gene therapy approaches to increase DDAH expression have shown promise in preclinical models, improving endothelial function and reducing atherosclerosis.⁵¹ Small molecule DDAH activators are in early development. Additionally, modulation of the gut microbiome, which influences ADMA metabolism through production of trimethylamine N-oxide and other metabolites, represents a novel therapeutic frontier.⁵² While these approaches remain largely experimental, they highlight the potential for targeted interventions in the ADMA pathway.

Clinical Applications and Future Directions

Risk Stratification and Prognosis

The most immediate clinical application of ADMA measurement lies in cardiovascular risk stratification and prognostic assessment. ADMA provides information about endothelial function and NO bioavailability that is not captured by traditional risk factors or biomarkers. In populations at intermediate cardiovascular risk, ADMA measurement might help identify individuals who would benefit from more aggressive preventive interventions.⁵³ In patients with established cardiovascular disease, ADMA could guide treatment intensity and help predict outcomes. The integration of ADMA into multibiomarker panels, combined with traditional risk factors and other novel biomarkers, may enhance risk prediction beyond current models.⁵⁴

Monitoring Therapeutic Interventions

Serial ADMA measurement could potentially be used to monitor response to cardiovascular therapies and guide treatment adjustments. Reductions in ADMA following initiation of statin therapy, antihypertensive treatment, or lifestyle interventions might indicate improved endothelial function and predict better outcomes.⁵⁵ However, the clinical utility of ADMA monitoring has not been established in randomized trials, and the optimal frequency and interpretation of serial measurements remain undefined. Studies demonstrating that treatment decisions guided by ADMA levels improve outcomes compared to standard care are needed before routine monitoring can be recommended.

Personalized Medicine Applications

ADMA measurement may facilitate personalized medicine approaches in cardiovascular disease. Genetic polymorphisms in DDAH and PRMT genes influence ADMA levels and may modify cardiovascular risk and treatment response.⁵⁶ Identifying patients with genetically determined high ADMA levels could enable targeted interventions. Similarly, ADMA levels might help identify patients most likely to benefit from specific therapies, such as those targeting the NO pathway. Integration of ADMA measurement with genetic, metabolomic, and other biomarker data could enable more precise cardiovascular risk assessment and treatment selection.

Challenges and Research Needs

Despite substantial evidence linking ADMA to cardiovascular disease, several challenges must be addressed before widespread clinical adoption. Standardization of measurement methods and establishment of universal reference ranges are essential. Large-scale prospective studies are needed to definitively establish ADMA’s incremental value over existing risk prediction tools and to determine optimal cutoff values for clinical decision-making.⁵⁷ Randomized trials testing whether ADMA-guided therapy improves outcomes compared to standard care are lacking. Additionally, the cost-effectiveness of ADMA testing in various clinical scenarios requires evaluation. Finally, development of effective therapies specifically targeting ADMA metabolism would strengthen the rationale for routine ADMA measurement.

Conclusions

Asymmetric dimethylarginine has emerged as a biologically plausible and clinically relevant biomarker of endothelial dysfunction and cardiovascular risk. As the principal endogenous inhibitor of nitric oxide synthase, ADMA plays a central role in regulating NO bioavailability and vascular function. Elevated ADMA levels are consistently associated with increased risk of cardiovascular disease, stroke, and mortality across diverse populations, with approximately 40% increased cardiovascular risk in meta-analyses. ADMA is markedly elevated in chronic kidney disease and correlates with erectile dysfunction, reflecting its role in systemic endothelial dysfunction.

Multiple factors influence ADMA levels, including testosterone, homocysteine, and oxidative stress, providing insights into mechanisms of cardiovascular disease. Reference ranges have been established using HPLC (0.34-1.10 μmol/L) and ELISA (0.25-0.92 μmol/L) methods, though standardization remains a challenge. While L-arginine supplementation has shown inconsistent results, several established cardiovascular therapies reduce ADMA levels, potentially contributing to their benefits.

Clinical applications include risk stratification, prognostic assessment, and potentially monitoring therapeutic interventions. However, challenges including measurement standardization, demonstration of incremental clinical value, and development of targeted therapies must be addressed. Future research should focus on large-scale prospective studies, randomized trials of ADMA-guided therapy, integration into multibiomarker strategies, and development of novel therapeutics targeting ADMA metabolism. With continued investigation and methodological refinement, ADMA measurement has the potential to enhance cardiovascular risk assessment and guide personalized therapeutic approaches.

References

1. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43(2):109-142.

2. Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J. 2012;33(7):829-837.

3. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J. 2001;357(Pt 3):593-615.

4. Lundberg JO, Weitzberg E. Nasal nitric oxide in man. Thorax. 1999;54(10):947-952.

5. Balligand JL, Ungureanu-Longrois D, Simmons WW, et al. Cytokine-inducible nitric oxide synthase (iNOS) expression in cardiac myocytes. J Biol Chem. 1994;269(44):27580-27588.

6. Schulz R, Kelm M, Heusch G. Nitric oxide in myocardial ischemia/reperfusion injury. Cardiovasc Res. 2004;61(3):402-413.

7. Schwarz PM, Kleinert H, Förstermann U. Potential functional significance of brain-type and muscle-type nitric oxide synthase I expressed in adventitia and media of rat aorta. Arterioscler Thromb Vasc Biol. 1999;19(11):2584-2590.

8. Wilcox JN, Subramanian RR, Sundell CL, et al. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscler Thromb Vasc Biol. 1997;17(11):2479-2488.

9. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339(8793):572-575.

10. Böger RH, Bode-Böger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998;98(18):1842-1847.

11. Leiper J, Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res. 1999;43(3):542-548.

12. Willeit P, Freitag DF, Laukkanen JA, et al. Asymmetric dimethylarginine and cardiovascular risk: systematic review and meta-analysis of 22 prospective studies. J Am Heart Assoc. 2015;4(6):e001833.

13. Valkonen VP, Päivä H, Salonen JT, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet. 2001;358(9299):2127-2128.

14. Schnabel R, Blankenberg S, Lubos E, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res. 2005;97(5):e53-e59.

15. Cavusoglu E, Ruwende C, Eng C, et al. Usefulness of baseline plasma asymmetric dimethylarginine levels to predict 1-year mortality in patients with non-ST-segment elevation myocardial infarction. Am J Cardiol. 2010;106(8):1089-1094.

16. Krempl TK, Maas R, Sydow K, Meinertz T, Böger RH, Kähler J. Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events. Eur Heart J. 2005;26(18):1846-1851.

17. Tang WH, Tong W, Shrestha K, et al. Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure. Eur Heart J. 2008;29(20):2506-2513.

18. Kielstein JT, Donnerstag F, Gasper S, et al. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke. 2006;37(8):2024-2029.

19. Böger RH. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the “L-arginine paradox” and acts as a novel cardiovascular risk factor. J Nutr. 2004;134(10 Suppl):2842S-2847S.

20. Antoniades C, Shirodaria C, Leeson P, et al. Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis. Eur Heart J. 2009;30(9):1142-1150.

21. Yoo JH, Lee SC. Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis. 2001;158(2):425-430.

22. Worthmann H, Chen S, Martens-Lobenhoffer J, et al. High plasma dimethylarginine levels are associated with adverse clinical outcome after stroke. J Atheroscler Thromb. 2011;18(9):753-761.

23. Schulze F, Carter AM, Schwedhelm E, et al. Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke. Atherosclerosis. 2010;208(2):518-523.

24. Notsu Y, Nabika T, Bokura H, Suyama Y, Kobayashi S, Yamaguchi S. Evaluation of asymmetric dimethylarginine and homocysteine in microangiopathy-related cerebral damage. Am J Hypertens. 2009;22(3):257-262.

25. Kielstein JT, Böger RH, Bode-Böger SM, et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol. 1999;10(3):594-600.

26. Zoccali C, Bode-Böger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001;358(9299):2113-2117.

27. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol. 2005;16(8):2449-2455.

28. Basar MM, Aydin G, Mert HC, Keles I, Caglayan O, Orkun S. Relationship between serum sex steroids and Aging Male Symptoms score and International Index of Erectile Function. Urology. 2005;66(3):597-601.

29. Bocchio M, Desideri G, Scarpelli P, et al. Endothelial cell activation in men with erectile dysfunction without cardiovascular risk factors and overt vascular damage. J Urol. 2004;171(4):1601-1604.

30. Sansone A, Romanelli F, Sansone M, Lenzi A, Di Luigi L. Folate: a possible role in erectile dysfunction? Aging Male. 2018;21(2):116-120.

31. Böger RH, Ron ES. L-Arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor. Altern Med Rev. 2005;10(1):14-23.

32. Stühlinger MC, Oka RK, Graf EE, et al. Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. Circulation. 2003;108(8):933-938.

33. Stühlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation. 2001;104(21):2569-2575.

34. Jones LC, Tran CT, Leiper JM, Hingorani AD, Vallance P. Common genetic variation in a basal promoter element alters DDAH2 expression in endothelial cells. Biochem Biophys Res Commun. 2003;310(3):836-843.

35. Leiper J, Murray-Rust J, McDonald N, Vallance P. S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci U S A. 2002;99(21):13527-13532.

36. Eid HM, Arnesen H, Hjerkinn EM, Lyberg T, Seljeflot I. Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine. Metabolism. 2004;53(12):1574-1579.

37. Teerlink T, Nijveldt RJ, de Jong S, van Leeuwen PA. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem. 2002;303(2):131-137.

38. Schulze F, Lenzen H, Hanefeld C, et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J. 2006;152(3):493.e1-8.

39. Schwedhelm E, Böger RH. Application of gas chromatography-mass spectrometry for analysis of isoprostanes: their role in cardiovascular disease. Clin Chem Lab Med. 2003;41(12):1552-1561.

40. Martens-Lobenhoffer J, Bode-Böger SM. Fast and efficient determination of arginine, symmetric dimethylarginine, and asymmetric dimethylarginine in biological fluids by hydrophilic-interaction liquid chromatography-electrospray tandem mass spectrometry. Clin Chem. 2006;52(3):488-493.

41. Schwedhelm E, Tan-Andresen J, Maas R, Riederer U, Schulze F, Böger RH. Liquid chromatography-tandem mass spectrometry method for the analysis of asymmetric dimethylarginine in human plasma. Clin Chem. 2005;51(7):1268-1271.

42. Blackwell S. The biochemistry, measurement and current clinical significance of asymmetric dimethylarginine. Ann Clin Biochem. 2010;47(Pt 1):17-28.

43. Kielstein JT, Salpeter SR, Bode-Boeger SM, Cooke JP, Fliser D. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function—a meta-analysis. Nephrol Dial Transplant. 2006;21(9):2446-2451.

44. Bode-Böger SM, Scalera F, Kielstein JT, et al. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol. 2006;17(4):1128-1134.

45. Schwedhelm E, Wallaschofski H, Atzler D, et al. Incidence of all-cause and cardiovascular mortality predicted by symmetric dimethylarginine in the population-based Study of Health in Pomerania. PLoS One. 2014;9(5):e96875.

46. Böger RH, Bode-Böger SM, Thiele W, Junker W, Alexander K, Frölich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation. 1997;95(8):2068-2074.

47. Maxwell AJ, Anderson BE, Cooke JP. Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBar. Vasc Med. 2000;5(1):11-19.

48. Schulman SP, Becker LC, Kass DA, et al. L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA. 2006;295(1):58-64.

49. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation. 1999;99(24):3092-3095.

50. Böger RH, Sydow K, Borlak J, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res. 2000;87(2):99-105.

51. Dayoub H, Achan V, Adimoolam S, et al. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation. 2003;108(24):3042-3047.

52. Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472(7341):57-63.

53. Meinitzer A, Seelhorst U, Wellnitz B, et al. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). Clin Chem. 2007;53(2):273-283.

54. Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2005;25(6):1102-1111.

55. Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J. 2003;24(21):1912-1919.

56. Maas R, Schulze F, Baumert J, et al. Asymmetric dimethylarginine, smoking, and risk of coronary heart disease in apparently healthy men: prospective analysis from the population-based Monitoring of Trends and Determinants in Cardiovascular Disease/Kooperative Gesundheitsforschung in der Region Augsburg study and experimental data. Clin Chem. 2007;53(4):693-701.

57. Böger RH. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res. 2003;59(4):824-833.